{"output": [["Novo Nordisk", "ORG", "Bid", "Ablynx", "ORG"], ["Ablynx", "ORG", "Refuse", "Novo Nordisk", "ORG"], ["Novo Nordisk", "ORG", "Operate_In", "Haemophilia Market", "SECTOR"], ["Novo Nordisk", "ORG", "Has", "Caplacizumab", "PRODUCT"], ["Novo Nordisk", "ORG", "Lose_Sales", "Hemlibra", "PRODUCT"], ["Novo Nordisk", "ORG", "CEO_Acts", "First_Acquisition", "EVENT"], ["Novo Nordisk", "ORG", "Discuss", "Global Blood Therapeutics", "ORG"], ["Novo Nordisk", "ORG", "Raise", "Bid", "FIN_INSTRUMENT"], ["Ablynx", "ORG", "Has", "Nano-bodies", "CONCEPT"], ["Ablynx", "ORG", "Partners", "Largest_Pharmaceutical_Companies", "ORG"], ["Ablynx", "ORG", "Specialize", "Novel_Drugs", "PRODUCT"], ["Ablynx", "ORG", "Has", "Caplacizumab", "PRODUCT"], ["Ablynx", "ORG", "Target", "Rheumatoid_Arthritis", "CONCEPT"], ["Ablynx", "ORG", "Target", "Psoriasis", "CONCEPT"], ["Ablynx", "ORG", "Target", "Cancer", "CONCEPT"]], "published": "2018-01-08T11:17:00.000+02:00"}